Search
The AREST CF experience in biobanking — More than just tissues, tubes and time Abstract Research to further improve outcomes for people with CF is
Research
‘Beyond core business’: A qualitative review of activities supporting environmental health within remote Western Australian schoolsAboriginal children and families contend with higher rates of preventable infectious diseases that can be attributed to their immediate living environment. The environments in which children spend most of their time are their homes and schools. We aimed to understand the opportunities in the school setting to support student skin health and wellbeing through environmental health activities, how these activities were completed, and the barriers to their implementation.
Research
Koolungar (Children) Moorditj (Strong) Healthy Skin Project Part II: Skin Health in Urban-Living Australian Aboriginal ChildrenAlthough essential for overall health and wellbeing, little is known about skin health in urban-living Australian Aboriginal children. This co-designed, research-service project aimed to describe skin health and document skin disease frequency in urban-living Aboriginal children and young people in Western Australia and investigate housing associations for skin infections.
Research
It’s not just droplets: a systematic review and meta-analysis of the modes of transmission of Group A StreptococcusThe transmission of Group A Streptococcus (Strep A) through respiratory droplets has been considered the dominant mode of transmission to date; however, little is known about the relative contribution of other modes of transmission. This review systematically summarises the contemporary evidence regarding the transmission of Strep A.
Research
Approaches that support Indigenous children and families in the transition to school: A systematic reviewThe early years are critical for lifelong wellbeing, with transition to formal school a key period for development. For Indigenous children, this transition provides opportunities to build on cultural strengths and belonging. However, many children face systemic barriers that impact their transition experiences, highlighting a need for culturally safe programs that support Indigenous families during this significant time.
Research
A microRNA-based dynamic risk score for type 1 diabetesIdentifying individuals at high risk of type 1 diabetes (T1D) is crucial as disease-delaying medications are available. Here we report a microRNA (miRNA)-based dynamic (responsive to the environment) risk score developed using multicenter, multiethnic and multicountry ('multicontext') cohorts for T1D risk stratification. Discovery (wet and dry lab) analysis identified 50 miRNAs associated with functional β cell loss, which is a hallmark of T1D.
Research
The CoolCot trial: active methods of therapeutic hypothermia for newborns with hypoxic ischaemic encephalopathy during neonatal transport: a study protocol for a randomised controlled trialImpaired oxygen delivery or blood flow to the brain around the time of birth can cause injury. Hypoxic ischaemic encephalopathy is a leading cause of death and disability in term and near-term infants.
Research
A general factor for trust?: Testing latent factor structures of trust across institutional and interpersonal contextsThe literature is replete with multi-dimensional self-report assessments of trust. It is not clear whether these dimensions are statistically distinguishable across institutional and interpersonal contexts, respectively.
Research
Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer TherapyMonoclonal antibodies are revolutionizing the landscape of current cancer treatment, bringing hope to patients with incurable cancers. B7-H3 (CD276) is an attractive therapeutic target for antibody-based therapy due to its low or absent expression in normal tissues and high expression in various types of tumors, including prostate cancer, pancreatic cancer, and high-mortality esophageal squamous cell carcinoma (ESCC). In recent years, various B7-H3-targeting antibodies have been developed for cancer treatment, with a few making their way to clinical trials.